BBIO – bridgebio pharma, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

BBIO

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

2/25

12:40 pm

BBIO

Rating for BBIO

Low Report

Rating for BBIO

Report

2/25

12:40 pm

BBIO

Rating for BBIO

Low Report

Rating for BBIO

Report

2/25

10:31 am

BBIO

Rating for BBIO

Low Report

Rating for BBIO

Report

2/25

10:31 am

BBIO

Rating for BBIO

Low Report

Rating for BBIO

Report

2/25

09:15 am

BBIO

Rating for BBIO

Medium Report

Rating for BBIO

Report

2/13

09:55 am

BBIO

Rating for BBIO

Low Report

Rating for BBIO

Report

2/13

09:55 am

BBIO

Rating for BBIO

Low Report

Rating for BBIO

Report

2/13

09:39 am

BBIO

Rating for BBIO

Low Report

Rating for BBIO

Report

2/13

09:39 am

BBIO

Rating for BBIO

Low Report

Rating for BBIO

Report

1/28

08:19 am

BBIO

Rating for BBIO

Low Report

Rating for BBIO

Report

1/28

08:19 am

BBIO

Rating for BBIO

Low Report

Rating for BBIO

Report

1/28

08:00 am

BBIO

BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.

Low Report

BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.

Report

1/27

04:24 pm

BBIO

BridgeBio initiated with an Overweight at Barclays

Low Report

BridgeBio initiated with an Overweight at Barclays

Report

1/27

04:24 pm

BBIO

BridgeBio initiated with an Overweight at Barclays

Low Report

BridgeBio initiated with an Overweight at Barclays

Report

1/20

10:48 am

BBIO

Rating for BBIO

Low Report

Rating for BBIO

Report

1/20

10:48 am

BBIO

Rating for BBIO

Low Report

Rating for BBIO

Report

1/6

10:46 am

BBIO

Rating for BBIO

Medium Report

Rating for BBIO

Report

1/6

10:46 am

BBIO

Rating for BBIO

Medium Report

Rating for BBIO

Report

1/6

09:00 am

BBIO

BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $96.00 price target on the stock.

Low Report

BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $96.00 price target on the stock.

Report

1/6

09:00 am

BBIO

BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $96.00 price target on the stock.

Low Report

BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $96.00 price target on the stock.

Report

1/6

05:09 am

BBIO

BridgeBio initiated with an Overweight at Morgan Stanley

Low Report

BridgeBio initiated with an Overweight at Morgan Stanley

Report

1/6

05:09 am

BBIO

BridgeBio initiated with an Overweight at Morgan Stanley

Low Report

BridgeBio initiated with an Overweight at Morgan Stanley

Report

12/16

05:43 am

BBIO

BridgeBio Pharma (NASDAQ:BBIO) was upgraded by analysts at Sanford C. Bernstein to a "strong-buy" rating.

Low Report

BridgeBio Pharma (NASDAQ:BBIO) was upgraded by analysts at Sanford C. Bernstein to a "strong-buy" rating.

Report

12/15

03:42 pm

BBIO

Rating for BBIO

Low Report

Rating for BBIO

Report

12/11

05:53 am

BBIO

Rating for BBIO

Low Report

Rating for BBIO

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.